Literature DB >> 2762315

Cationic liposome-mediated RNA transfection.

R W Malone1, P L Felgner, I M Verma.   

Abstract

We have developed an efficient and reproducible method for RNA transfection, using a synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), incorporated into a liposome (lipofectin). Transfection of 10 ng to 5 micrograms of Photinus pyralis luciferase mRNA synthesized in vitro into NIH 3T3 mouse cells yields a linear response of luciferase activity. The procedure can be used to efficiently transfect RNA into human, rat, mouse, Xenopus, and Drosophila cells. Using the RNA/lipofectin transfection procedure, we have analyzed the role of capping and beta-globin 5' and 3' untranslated sequences on the translation efficiency of luciferase RNA synthesized in vitro. Following transfection of NIH 3T3 cells, capped mRNAs with beta-globin untranslated sequences produced at least 1000-fold more luciferase protein than mRNAs lacking these elements.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2762315      PMCID： PMC297778          DOI： 10.1073/pnas.86.16.6077

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  15 in total

1.  Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.

Authors:  S van der Werf; J Bradley; E Wimmer; F W Studier; J J Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  5'-Terminal 7-methylguanosine and mRNA function: influence of potassium concentration on translation in vitro.

Authors:  L A Weber; E D Hickey; D L Nuss; C Baglioni
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

3.  Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.

Authors:  P A Krieg; D A Melton
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

4.  Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements.

Authors:  J J Dunn; F W Studier
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

Review 5.  5'-terminal cap structure in eucaryotic messenger ribonucleic acids.

Authors:  A K Banerjee
Journal:  Microbiol Rev       Date:  1980-06

6.  Importance of initiation factor preparations in the translation of reovirus and globin mRNAs lacking a 5'-terminal 7-methylguanosine.

Authors:  W A Held; K West; J F Gallagher
Journal:  J Biol Chem       Date:  1977-12-10       Impact factor: 5.157

7.  Multicomponent RNA plant virus infection derived from cloned viral cDNA.

Authors:  P Ahlquist; R French; M Janda; L S Loesch-Fries
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

8.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

Authors:  F W Studier; B A Moffatt
Journal:  J Mol Biol       Date:  1986-05-05       Impact factor: 5.469

9.  Firefly luciferase gene: structure and expression in mammalian cells.

Authors:  J R de Wet; K V Wood; M DeLuca; D R Helinski; S Subramani
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

10.  Poly(A) shortening and degradation of the 3' A+U-rich sequences of human c-myc mRNA in a cell-free system.

Authors:  G Brewer; J Ross
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272
View more
  167 in total

Review 1.  RNA-transfected dendritic cells in cancer immunotherapy.

Authors:  D A Mitchell; S K Nair
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo.

Authors:  Dominique Lévesque; Sanaa Choufani; Jean-Pierre Perreault
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

3.  trans-dominant inhibition of human hepatitis delta virus genome replication.

Authors:  J S Glenn; J M White
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  In vivo analysis of the promoter structure of the influenza virus RNA genome using a transfection system with an engineered RNA.

Authors:  K Yamanaka; N Ogasawara; H Yoshikawa; A Ishihama; K Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

6.  Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation.

Authors:  Dan Zheng; David A Giljohann; David L Chen; Matthew D Massich; Xiao-Qi Wang; Hristo Iordanov; Chad A Mirkin; Amy S Paller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

Review 7.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

Review 8.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

Review 9.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells.

Authors:  S Zou; K Scarfo; M H Nantz; J G Hecker
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.